Concepts (84)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 7 | 2022 | 432 | 1.310 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2013 | 57 | 0.600 |
Why?
|
| Anti-Retroviral Agents | 2 | 2021 | 16 | 0.450 |
Why?
|
| Herpes Zoster | 1 | 2013 | 3 | 0.440 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 5 | 0.430 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 10 | 0.430 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 46 | 0.420 |
Why?
|
| Oseltamivir | 1 | 2011 | 1 | 0.390 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 14 | 0.390 |
Why?
|
| Inappropriate Prescribing | 1 | 2011 | 5 | 0.390 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 157 | 0.380 |
Why?
|
| Influenza, Human | 1 | 2011 | 39 | 0.380 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 67 | 0.380 |
Why?
|
| Health Services | 1 | 2011 | 8 | 0.370 |
Why?
|
| Antiviral Agents | 1 | 2011 | 67 | 0.370 |
Why?
|
| Fluconazole | 1 | 2010 | 7 | 0.350 |
Why?
|
| Mycoses | 1 | 2010 | 20 | 0.350 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2010 | 17 | 0.350 |
Why?
|
| Antifungal Agents | 1 | 2010 | 34 | 0.340 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2010 | 30 | 0.340 |
Why?
|
| Pandemics | 1 | 2011 | 233 | 0.330 |
Why?
|
| Anti-HIV Agents | 2 | 2022 | 63 | 0.270 |
Why?
|
| United States | 4 | 2013 | 1899 | 0.270 |
Why?
|
| Female | 11 | 2022 | 13845 | 0.260 |
Why?
|
| Electronic Health Records | 2 | 2022 | 58 | 0.210 |
Why?
|
| Risk Factors | 4 | 2012 | 2167 | 0.200 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2022 | 5 | 0.200 |
Why?
|
| Adult | 6 | 2021 | 7087 | 0.190 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2021 | 4 | 0.190 |
Why?
|
| Humans | 11 | 2022 | 25181 | 0.190 |
Why?
|
| Male | 8 | 2021 | 13545 | 0.180 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 87 | 0.180 |
Why?
|
| Middle Aged | 6 | 2021 | 8136 | 0.170 |
Why?
|
| HIV-1 | 1 | 2021 | 210 | 0.160 |
Why?
|
| Mass Screening | 1 | 2019 | 161 | 0.150 |
Why?
|
| Infant, Newborn | 2 | 2021 | 522 | 0.120 |
Why?
|
| Chicago | 2 | 2019 | 782 | 0.110 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2013 | 2 | 0.110 |
Why?
|
| Herpesvirus 3, Human | 1 | 2013 | 4 | 0.110 |
Why?
|
| Health Care Surveys | 1 | 2013 | 57 | 0.110 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 49 | 0.110 |
Why?
|
| RNA, Viral | 1 | 2013 | 40 | 0.110 |
Why?
|
| Viral Load | 1 | 2013 | 71 | 0.110 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2012 | 10 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 122 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 116 | 0.100 |
Why?
|
| Women's Health | 1 | 2013 | 171 | 0.090 |
Why?
|
| Adolescent | 2 | 2019 | 1998 | 0.090 |
Why?
|
| Pregnancy | 1 | 2012 | 303 | 0.090 |
Why?
|
| Incidence | 1 | 2013 | 664 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2011 | 243 | 0.090 |
Why?
|
| Sex Factors | 1 | 2012 | 429 | 0.090 |
Why?
|
| HIV | 1 | 2011 | 35 | 0.090 |
Why?
|
| Minority Groups | 1 | 2011 | 66 | 0.090 |
Why?
|
| Disease Progression | 1 | 2013 | 649 | 0.090 |
Why?
|
| Cholestasis | 1 | 2010 | 7 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 438 | 0.090 |
Why?
|
| Candidiasis | 1 | 2010 | 17 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 467 | 0.090 |
Why?
|
| Infant, Premature, Diseases | 1 | 2010 | 23 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 832 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 276 | 0.090 |
Why?
|
| Infant, Premature | 1 | 2010 | 164 | 0.080 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2010 | 152 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2013 | 1588 | 0.080 |
Why?
|
| Child | 1 | 2011 | 1232 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2010 | 3146 | 0.050 |
Why?
|
| Cyclohexanes | 1 | 2021 | 2 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 46 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2021 | 136 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 129 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 102 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2021 | 413 | 0.040 |
Why?
|
| HIV Antigens | 1 | 2019 | 11 | 0.040 |
Why?
|
| HIV Antibodies | 1 | 2019 | 16 | 0.040 |
Why?
|
| Program Development | 1 | 2019 | 58 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 117 | 0.040 |
Why?
|
| Urban Population | 1 | 2019 | 131 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2021 | 277 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 282 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 222 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2021 | 1757 | 0.030 |
Why?
|
| Aged | 2 | 2021 | 8400 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 4503 | 0.010 |
Why?
|